Pr PETIT Thierry

Prognostic value of [F]FDG PET/CT and PERCIST criteria in patients with HER2-low metastatic breast cancer treated with trastuzumab deruxtecan.

Frega J, Somme L, Martin T, Petit T, Salvadori J, Bund C, Somme F

Eur J Nucl Med Mol Imaging. 2026 07 1;:

Effectiveness of pegylated liposomal doxorubicin (Caelyx®) monotherapy in patients with metastatic HER2-low breast cancer: a monocentric retrospective study.

Boudier P, Bischoff H, Somme L, Pflumio C, Kalish M, Fischbach C, Velten M, Petit T

Cancer Treat Res Commun. 2026 06 10;48:101276

Characteristics, treatment and survival of older patients with metastatic triple negative breast cancer from the ESME mBC real-world national cohort: a comparison with younger women.

Mairé M, Bouteiller F, Chakiba C, Jacot W, Geiss R, Ung M, Goncalves A, Frenel JS, Bailleux C, Perrin C, Massard V, Mailliez A, Jouannaud C, Cherifi F, Petit T, Terret C, Viansone A, Bosquet L, Galvin A

Breast. 2026 05 22;88:104816

Characteristics and outcomes of patients with HER2-negative metastatic breast cancers with low expression of estrogen and progesterone receptors in the multicenter ESME cohort.

Alexandre M, Teruel E, Dalenc F, de la Motte Rouge T, Brain E, Massard V, Arnedos M, Mailliez A, Ferrero JM, Bachelot T, Desmoulins I, Mouret-Reynier MA, Levy C, Gonçalves A, Berghian A, Petit T, Frenel JS, Martin AL, Grinda T, Jacot W

Breast. 2026 05 18;88:104815

Advanced high-grade serous ovarian cancer treated with intensive cytoreductive surgery and chemotherapy: prognostic impact of lymph node involvement: analysis of the French national ESME-Unicancer database.

Le Bars S, Guerin-Charbonnel C, Martin E, Thomas QD, Costaz H, Pomel C, Marchal F, Narducci F, Gouy S, Laas E, Rossi L, Lambaudie E, Rouzier R, Petit T, Gladieff L, De La Motte Rouge T, Bosquet L, Colombo PE, Classe JM, Loaec C

Eur J Surg Oncol. 2026 03 25;52(6):111768

Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer.

Lynce F, Valenza C, Niman SM, Bertucci F, Kai M, Ryan S, Troll E, Layman RM, Fanucci KA, Giordano A, Nasrazadani A, Nakhlis F, Bellon J, Warren L, Block C, Schumer S, Lucci A, Krishnamurthy S, Trapani D, Lerebours F, Dalenc F, Levy C, Petit T, Leheurteur M, Bachelot T, Tredan O, Ribeiro JM, Pistilli B, Zagami P, Ladoire S, Lopez Almeida L, Zemmour C, Carey LA, Tolaney SM, Valero V, ,Curigliano G, Regan MM, Goncalves A, Woodward WA

ESMO Open. 2026 01 19;11(2):106050

CDK4/6 Inhibitors in HER2-positive Metastatic Breast Cancer.

Bischoff H, Petit T

Clin Breast Cancer. 2026 01 9;26(2):93-104

F-Fluorodeoxyglucose PET-CT evaluation after one course of neoadjuvant therapy fails to predict pCR in HER2 + BC patients: a prospective and multicentric French study.

Chanchou M, Mouret-Reynier MA, Molnar I, Deshayes E, D'Hondt V, Bourahla K, Petit T, Bardet S, Levy C, Morel O, Augereau P, Rousseau C, Campone M, Monteil J, Venat-Bouvet L, Faye A, Benavent V, Cachin F

Breast Cancer Res. 2025 12 3;:

Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial - BREASTIMMUNE-0

Trédan O, Loirat D, Chabaud S, Toussaint P, Petit T, Viret F, Levy C, Robert A, Grenier J, Mansi L, Spano JP, Patsouris A, Derbel O, Jouannaud C, Ferrero JM, Frenel JS, Molin Y, Doublet L, Heudel PE, Pierga JY, Garin G, Pérol D, Bachelot T

Breast. 2025 11 21;85:104648

Letrozole to prevent breast cancer in postmenopausal women with BRCA1/2 mutations (LIBER study).

Pujol P, Roca L, Lortholary A, Lasset C, Crivelli L, Berthet P, Tennevet I, Petit T, Chabbert-Buffet N, Gesta P, Saule C, Chiesa J, Nguyen TD, Mailliez A, Callet NA, Noguès C, Dreyfus H, Delnatte C, Prieur F, Gladieff L, Ingster O, Galibert V, Lemonnier J, Delaloge S

Eur J Cancer. 2025 11 7;231:116101

Optimizing Post-Neoadjuvant Treatment in Early Triple-Negative Breast Cancer.

Bischoff H, Somme L, Petit T

Cancers (Basel). 2025 10 10;17(20):

Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohort.

Varnier R, Pérol D, Jacot W, Mailliez A, Diéras V, Dalenc F, Gonçalves A, Levy C, Arnedos M, Frenel JS, Bailleux C, Massard V, Brain E, Sauterey B, Savoye AM, Bosquet L, Thery JC, Petit T, Bachelot T, Grinda T, Ray-Coquard I

ESMO Open. 2025 09 17;10(10):105803

Effect of Breast Surgery on Quality of Life in BRCA Mutation Carriers With Invasive Breast Cancer: A CANTO Database Study.

Mahiou K, Bonneau C, Coutant C, Martin AL, Gaudin C, Fournier M, Jacot W, Kieffer A, Sauterey B, Tredan O, Campone M, Tarpin C, Lerebours F, Mouret-Reynier MA, Petit T, Guillermet S, Constantin G, Bertaut A

Clin Breast Cancer. 2025 09 4;:

Risk models of cancer related cognitive complaints among early breast cancer survivors in the CANTO cohort.

Presti D, Di Meglio A, Havas J, Pagliuca M, Cheaib B, Martin AL, Gaudin C, Jouannaud C, Fournier M, Kieffer A, Campone M, Lerebours F, Petit T, Boyault S, Bertaut A, Tredan O, Cherifi F, Lange M, Pradon C, Vaz-Luis I, Joly F

J Natl Cancer Inst. 2025 09 3;:

Role of platinum-free interval (PFI) and maintenance therapies in recurrent ovarian cancer to explain survival. An analysis from the French real-world ESME Ovarian Database.

Chator C, Chevrier M, Frenel JS, Guyon F, Sabatier R, Pomel C, Rouge TM, Pautier P, Gladieff L, Follana P, Colombo PE, Petit T, Guillemet C, Marchal F, Narducci F, Fumet JD, Rodrigues M, Bosquet L, Rouzier R, Ray-Coquard I

Gynecol Oncol. 2025 08 7;201:17-25

Eribulin efficacy in long responder patients with metastatic breast cancer: A multicentric observational study.

Passildas J, Paillard MJ, Uwer L, Molnar I, Dohollou N, Petit T, Hajjaji N, Boudin L, Lorgis V, Jacquin JP, Abrial C, Mouret-Reynier MA

Cancer Epidemiol. 2025 03 15;96:102800

Tumor-intrinsic chemosensitivity assessed by KELIM and prognosis by status in patients with advanced ovarian carcinomas.

Becker O, Durand A, Chevrier M, Collet L, Gladieff L, Joly F, Sauterey B, Pomel C, Costaz H, Pautier P, Guillemet C, de la Motte Rouge T, Sabatier R, Classe JM, Petit T, Leblanc E, Marchal F, Colombo PE, Barranger E, Savoye AM, Bosquet L, Ray-Coquard I, Carton M, Colomban O, You B, Rodrigues M

Int J Gynecol Cancer. 2024 10 31;:

Long-term behavioral symptom clusters among survivors of early-stage breast cancer. development and validation of a predictive model.

Pagliuca M, Havas J, Thomas E, Drouet Y, Soldato D, Franzoi MA, Ribeiro J, Chiodi CK, Gillanders E, Pistilli B, Menvielle G, Joly F, Lerebours F, Rigal O, Petit T, Giacchetti S, Dalenc F, Wassermann J, Arsene O, Martin AL, Everhard S, Tredan O, Boyault S, De Laurentiis M, Viari A, Deleuze JF, Bertaut A, André F, Vaz-Luis I, Di Meglio A

J Natl Cancer Inst. 2024 09 9;:

Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer.

Bischoff H, Espié M, Petit T

Curr Treat Options Oncol. 2024 08 17;:

Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer.

Bischoff H, Espié M, Petit T

Curr Treat Options Oncol. 2024 08 15;:

Metabolomic prediction of breast cancer treatment induced neurological and metabolic toxicities.

Piffoux M, Jacquemin J, Pétéra M, Durand S, Abila A, Centeno D, Joly C, Lyan B, Martin AL, Everhard S, Boyault S, Pistilli B, Fournier M, Rouanet P, Havas J, Sauterey B, Campone M, Tarpin C, Mouret-Reynier MA, Rigal O, Petit T, Lasset C, Bertaut A, Cottu P, Andre F, Vaz-Luis I, Pujos-Guillot E, Drouet Y, Trédan O

Clin Cancer Res. 2024 08 6;:

Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort.

Epaillard N, Lusque A, Jacot W, Mailliez A, Bachelot T, Arnedos M, Le Du F, Brain E, Ferrero JM, Massard V, Desmoulins I, Mouret-Reynier MA, Levy C, Gonçalves A, Leheurteur M, Petit T, Filleron T, Bosquet L, Pistilli B, Frenel JS

ESMO Open. 2024 05 3;9(5):103447

Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.

Petit T, Hajjaji N, Antoine EC, Benderra MA, Gozy M, Foa C, Mouysset JL, Grenier J, Mousseau M, Mailliez A, Saghatchian M, Lachaier E, Desmoulins I, Hennequin A, Maes P, Loirat D, Ricci F, Diéras V, Berton D, Tiong FL, Teixeira L, Dohollou N, Lévy C, Bachelot T, Pierga JY

Cancer Med. 2024 05;13(9):e7168

Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.

Ginzac A, Molnar I, Durando X, Motte Rouge T, Petit T, D'hondt V, Campone M, Bonichon-Lamichhane N, Venat Bouvet L, Levy C, Augereau P, Pistilli B, Arsene O, Jouannaud C, Nguyen S, Cayre A, Tixier L, Mahier Ait Oukhatar C, Nabholtz JM, Penault-Llorca F, Mouret-Reynier MA

Breast Cancer Res Treat. 2024 03 7;:

Low RNA disruption during neoadjuvant chemotherapy predicts pCR absence in patients with breast cancer.

Cazzaniga ME, Ademuyiwa F, Petit T, Tio J, Generali D, Ciruelos EM, Califaretti N, Poirier B, Ardizzoia A, Hoenig A, Lex B, Mouret-Reynier MA, Giesecke D, Isambert N, Masetti R, Pitre L, Wrobel D, Augereau P, Milani M, Rask S, Solbach C, Pritzker L, Noubir S, Parissenti A, Trudeau M

JNCI Cancer Spectr. 2023 12 19;:

First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort.

Galvin A, Courtinard C, Bouteiller F, Gourgou S, Dalenc F, Jacot W, Arnedos M, Bailleux C, Dieras V, Petit T, Emile G, Dubray-Longeras P, Frenel JS, Bachelot T, Mailliez A, Brain E, Desmoulins I, Massard V, Patsouris A, Goncalves A, Grinda T, Delaloge S, Bellera C

Eur J Cancer. 2023 11 10;196:113422

Chemotherapy-Related Amenorrhea and Quality of Life Among Premenopausal Women With Breast Cancer.

Kabirian R, Franzoi MA, Havas J, Coutant C, Tredan O, Levy C, Cottu P, Dhaini Mérimèche A, Guillermet S, Ferrero JM, Giacchetti S, Petit T, Dalenc F, Rouanet P, Everhard S, Martin AL, Pistilli B, Lambertini M, Vaz-Luis I, Di Meglio A

JAMA Netw Open. 2023 11 1;6(11):e2343910

Anaplastic Lymphoma Kinase Inhibitor-Induced Neutropenia: A Systematic Review.

Moinard-Butot F, Nannini S, Fischbach C, Abdallahoui S, Demarchi M, Petit T, Bender L, Schott R

Cancers (Basel). 2023 10 11;15(20):

Capecitabine efficacy after cycline-dependent-kinase 4/6 inhibitor plus endocrine therapy in metastatic hormone receptor-positive breast cancer.

Bender L, Pflumio C, Trensz P, Pierard L, Kalish M, Fischbach C, Petit T

Cancer Treat Res Commun. 2023 06 25;36:100738

Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort.

Grinda T, Antoine A, Jacot W, Cottu PH, de la Motte Rouge T, Frenel JS, Mailliez A, Dalenc F, Goncalves A, Clatot F, Mouret Reynier MA, Levy C, Ferrero JM, Desmoulins I, Uwer L, Petit T, Jouannaud C, Arnedos M, Chevrot M, Courtinard C, Tredan O, Brain E, Pérol D, Pistilli B, Delaloge S

Eur J Cancer. 2023 06 7;189:112935

Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation.

Frenel JS, Lusque A, Delaloge S, Ferrero JM, Bachelot T, Desmoulins I, Levy C, Eymard JC, Gonçalves A, Patsouris A, Reynier MAM, Thery MJ, Petit T, Cabel L, Uwer L, Debled M, Chevrot M, Mailliez A, Jacot W, de La Motte Rouge T

Br J Cancer. 2023 04 3;:

Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials.

Rassy E, Filleron T, Viansone A, Lacroix-Triki M, Rivera S, Desmoulins I, Serin D, Canon JL, Campone M, Gonçalves A, Levy C, Cottu P, Petit T, Eymard JC, Debled M, Bachelot T, Dalenc F, Roca L, Lemonnier J, Delaloge S, Pistilli B

Breast Cancer Res Treat. 2023 03 29;:

Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database.

Courtinard C, Gourgou S, Jacot W, Carton M, Guérin O, Vacher L, Bertaut A, Le Deley MC, Pérol D, Marino P, Levy C, Uwer L, Perrocheau G, Schiappa R, Bachelot F, Parent D, Breton M, Petit T, Filleron T, Loeb A, Pélissier SM, Robain M, Delaloge S, Bellera C

BMC Med. 2023 03 8;21(1):87

Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study.

François-Martin H, Lardy-Cléaud A, Pistilli B, Levy C, Diéras V, Frenel JS, Guiu S, Mouret-Reynier MA, Mailliez A, Eymard JC, Petit T, Ung M, Desmoulins I, Augereau P, Bachelot T, Uwer L, Debled M, Ferrero JM, Clatot F, Goncalves A, Chevrot M, Chabaud S, Cottu P

Cancers (Basel). 2023 02 13;15(4):

Baseline quality of life and chemotherapy toxicities in patients with early breast cancer.

Licaj I, Coquan E, Dabakuyo-Yonli TS, Dauchy S, Vaz Luis I, Charles C, Lemogne C, Tredan O, Vanlemmens L, Jouannaud C, Levy C, Rigal O, Fournier M, Petit T, Dalenc F, Rouanet P, Lemonnier J, Everhard S, Cottu P, Joly F

Cancer. 2023 01 15;:

A propensity score-weighted study comparing a two- versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer.

Bischoff H, Bigot C, Moinard-Butot F, Pflumio C, Fischbach C, Kalish M, Kurtz JE, Pierard L, Demarchi M, Karouby D, Coliat P, Pivot X, Petit T, Cox DG, Goepp L, Bender L, Trensz P

Breast Cancer Res Treat. 2022 12 23;:

Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes.

Carausu M, Carton M, Diéras V, Petit T, Guiu S, Gonçalves A, Augereau P, Ferrero JM, Levy C, Ung M, Desmoulins I, Debled M, Bachelot T, Pistilli B, Frenel JS, Mailliez A, Chevrot M, Cabel L

JAMA Netw Open. 2022 12 1;5(12):e2247154

[Therapeutic strategies for the treatment of endocrine resistant hormone receptor positive advanced breast cancer].

Grellety T, Hajjaji N, Petit T, Bailleux C

Bull Cancer. 2022 10 25;:

Consequences of Discontinuing a 4/6 Cyclin D-Dependent Kinase Inhibitor During Endocrine Treatment in Hormone-Sensitive Metastatic Breast Cancer Patients in the Context of the COVID-19 Outbreak.

Martin S, Pflumio C, Trensz P, Schaff-Wendling F, Weindling MK, Fischbach C, Pierard L, Limacher JM, Nader R, Velten M, Petit T

Clin Breast Cancer. 2022 10 13;:

Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database.

Mailliez A, D'Hondt V, Lusque A, Caron O, Cabel L, Goncalves A, Debled M, Gladieff L, Ferrero JM, Petit T, Mouret-Reynier MA, Eymard JC, Levy C, Uwer L, Leheurteur M, Desmoulins I, Bachelot T, Frenel ES, De la Motte Rouge T, Simon G, Jacot W, Delaloge S

Int J Cancer. 2022 09 26;:

Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France.

de Calbiac O, Lusque A, Mailliez A, Bachelot T, Uwer L, Mouret-Reynier MA, Emile G, Jouannaud C, Gonçalves A, Patsouris A, Diéras V, Leheurteur M, Petit T, Cottu P, Ferrero JM, D'Hondt V, Desmoulins I, Mourato-Ribeiro J, Martin AL, Frenel JS

JAMA Netw Open. 2022 09 1;5(9):e2231170

Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study.

Vasseur A, Carton M, Guiu S, Augereau P, Uwer L, Mouret-Reynier MA, Levy C, Eymard JC, Ferrero JM, Leheurteur M, Goncalves A, Robert M, De La Motte Rouge T, Bachelot T, Petit T, Debled M, Grinda T, Desmoulins I, Vanlemmens L, Nicolaï V, Simon G, Cabel L

Breast. 2022 08 4;65:136-144

Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: A systematic literature review.

Schmitt M, Menoux I, Chambrelant I, Hild C, Petit T, Mathelin C, Noël G

Transl Oncol. 2022 08;22:101456

Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort.

Moinard-Butot F, Saint-Martin C, Pflumio C, Carton M, Jacot W, Cottu PH, Diéras V, Dalenc F, Goncalves A, Debled M, Patsouris A, Mouret-Reynier MA, Vanlemmens L, Leheurteur M, Emile G, Ferrero JM, Desmoulins I, Uwer L, Eymard JC, Cheaib B, Courtinard C, Bachelot T, Chevrot M, Petit T

Breast. 2022 Mar 11;63:54-60

Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study.

Dalenc F, Lusque A, De La Motte Rouge T, Pistilli B, Brain E, Pasquier D, Debled M, Thery JC, Gonçalves A, Desmoulins I, Levy C, Uwer L, Ferrero JM, Eymard JC, Mouret-Reynier MA, Patsouris A, Frenel JS, Petit T, Chevrot M, Bachelot T, Guiu S

Eur J Cancer. 2022 Feb 14;164:70-79

The Impact of an Incidental Dose on Axillary Tumor Control and Toxicity in Localized Breast Cancer: A Retrospective Analysis.

Schmitt M, Chambrelant I, Hong Chheang P, Pflumio C, Hild C, Petit T, Noël G

Cancers (Basel). 2022 Feb 4;14(3):

Enrollment of older metastatic breast cancer patients in first-line clinical trials: 9-year experience of the large-scale real-life multicenter French ESME cohort.

Bringuier M, Carton M, Levy C, Patsouris A, Pasquier D, Debled M, Rigal O, Jacot W, Gonçalves A, Desmoulins I, De La Motte Rouge T, Bachelot T, Ferrero JM, Eymard JC, Ung M, Mouret-Reynier MA, Petit T, Chevrot M, Uwer L, Courtinard C, Frenel JS, Vianzone A, Baldini C

Breast Cancer Res Treat. 2022 Jan 5;:

Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database.

Carausu M, Carton M, Cabel L, Patsouris A, Levy C, Verret B, Pasquier D, Debled M, Gonçalves A, Desmoulins I, Lecouillard I, Bachelot T, Ferrero JM, Eymard JC, Mouret-Reynier MA, Chevrot M, De Maio E, Uwer L, Frenel JS, Leheurteur M, Petit T, Darlix A, Bozec L

Ther Adv Med Oncol. 2022 ;14:17588359221077082

Real-world evidence of the management and prognosis of young women (⩽40 years) with metastatic breast cancer.

Mallet A, Lusque A, Levy C, Pistilli B, Brain E, Pasquier D, Debled M, Thery JC, Gonçalves A, Desmoulins I, De La Motte Rouge T, Faure C, Ferrero JM, Eymard JC, Mouret-Reynier MA, Patsouris A, Cottu P, Dalenc F, Petit T, Payen O, Uwer L, Guiu S, Sébastien Frenel J

Ther Adv Med Oncol. 2022 ;14:17588359211070362

Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer.

Corbaux P, Lardy-Cleaud A, Alexandre M, Fontanilles M, Lévy C, Viansone AA, Mailliez A, Debled M, Goncalves A, Le Du F, Lerebours F, Ferrero JM, Eymard JC, Mouret-Reynier MA, Petit T, Frenel JS, Dalenc F, Courtinard C, Chaix M, Bachelot T

Breast Cancer Res Treat. 2021 Oct 23;:

De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis.

Gaillard T, Carton M, Mailliez A, Desmoulins I, Mouret-Reynier MA, Petit T, Leheurteur M, Dieras V, Ferrero JM, Uwer L, Guiu S, Gonçalves A, Levy C, Debled M, Dalenc F, Patsouris A, Bachelot T, Eymard JC, Chevrot M, Conversano A, Robain M, Hequet D

Eur J Cancer. 2021 Oct 21;158:181-188

Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database.

Annonay M, Gauquelin L, Geiss R, Ung M, Cristol-Dalstein L, Mouret-Reynier MA, Goncalves A, Abadie-Lacourtoisie S, Francois E, Perrin C, Le Fel J, Lorgis V, Servent V, Uwer L, Jouannaud C, Leheurteur M, Joly F, Campion L, Courtinard C, Villacroux O, Petit T, Soubeyran P, Terret C, Bellera C, Brain E, Delaloge S

Breast. 2021 Oct 1;60:138-146

Multicenter evaluation of breast cancer patients' satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic.

Bizot A, Karimi M, Rassy E, Heudel PE, Levy C, Vanlemmens L, Uzan C, Deluche E, Genet D, Saghatchian M, Giacchetti S, Grenier J, Patsouris A, Dieras V, Pierga JY, Petit T, Ladoire S, Jacot W, Benderra MA, De Jesus A, Delaloge S, Lambertini M, Pistilli B

Br J Cancer. 2021 Sep 29;:

Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME).

Dano D, Lardy-Cleaud A, Monneur A, Quenel-Tueux N, Levy C, Mouret-Reynier MA, Coudert B, Mailliez A, Ferrero JM, Guiu S, Campone M, de La Motte Rouge T, Petit T, Pistilli B, Dalenc F, Simon G, Lerebours F, Chabaud S, Bertucci F, Gonçalves A

ESMO Open. 2021 Jul 22;6(4):100220

Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database.

De Nonneville A, Zemmour C, Frank S, Joly F, Ray-Coquard I, Costaz H, Classe JM, Floquet A, De la Motte Rouge T, Colombo PE, Sauterey B, Leblanc E, Pomel C, Marchal F, Barranger E, Savoye AM, Guillemet C, Petit T, Pautier P, Rouzier R, Gladieff L, Simon G, Courtinard C, Sabatier R

Gynecol Oncol. 2021 Jul 19;:

Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database.

Carausu M, Carton M, Darlix A, Pasquier D, Leheurteur M, Debled M, Mouret-Reynier MA, Goncalves A, Dalenc F, Verret B, Campone M, Augereau P, Ferrero JM, Levy C, Fumet JD, Lefeuvre-Plesse C, Petit T, Uwer L, Jouannaud C, Larrouquere L, Chevrot M, Courtinard C, Cabel L

ESMO Open. 2021 May 10;6(3):100150

Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort.

Grinda T, Antoine A, Jacot W, Blaye C, Cottu PH, Diéras V, Dalenc F, Gonçalves A, Debled M, Patsouris A, Mouret-Reynier MA, Mailliez A, Clatot F, Levy C, Ferrero JM, Desmoulins I, Uwer L, Petit T, Jouannaud C, Lacroix-Triki M, Deluche E, Robain M, Courtinard C, Bachelot T, Brain E, Pérol D, Delaloge S

ESMO Open. 2021 Apr 22;6(3):100114

Unhealthy behaviors after breast cancer: Capitalizing on a teachable moment to promote lifestyle improvements.

Di Meglio A, Gbenou AS, Martin E, Pistilli B, Ligibel JA, Crane TE, Flaysakier JD, Minvielle E, Vanlemmens L, Guenancia C, Rigal O, Fournier M, Soulie P, Mouret-Reynier MA, Tarpin C, Boiffard F, Guillermet S, Everhard S, Martin AL, Giacchetti S, Petit T, Dalenc F, Rouanet P, Arnaud A, Andre F, Vaz-Luis I

Cancer. 2021 Apr 22;:

Early Locoregional Breast Surgery and Survival in de novo Metastatic Breast Cancer in the Multicenter National ESME Cohort.

Hotton J, Lusque A, Leufflen L, Campone M, Levy C, Honart JF, Mailliez A, Debled M, Gutowski M, Leheurteur M, Gonçalves A, Jankowski C, Guillermet S, Bachelot T, Ferrero JM, Eymard JC, Petit T, Pouget N, de La Lande B, Frenel JS, Villacroux O, Simon G, Pons-Tostivint E, Marchal F

Ann Surg. 2021 Feb 1;:

Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program.

Cabel L, Carton M, Pistilli B, Dalenc F, Vanlemnens L, Levy C, Jacot W, Debled M, Loeb A, Hennequin A, De la Motte Rouge T, Laborde L, Laurent C, Chamorey E, Parent D, Petit T, Mouret-Reynier MA, Campone M, Perrocheau G, Labreveux C, Bachelot T, Robain M, Lerebours F

Breast. 2021 Jan 30;56:18-25

A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab.

Demarchi M, Coliat P, Barthelemy P, Schott R, BenAbdelghani M, Kim M, Hii JCS, Feyaerts P, Ang FRX, Derde MP, Deforce F, Petit T, Schwabe C, Wynne C, Park LS, Pivot X

PLoS One. 2021 ;16(9):e0248222

Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program.

Bertho M, Fraisse J, Patsouris A, Cottu P, Arnedos M, Pérol D, Jaffré A, Goncalves A, Lebitasy MP, D'Hondt V, Dalenc F, Ferrero JM, Levy C, Dabakuyo S, Rouzier R, Penault-Llorca F, Uwer L, Eymard JC, Breton M, Chevrot M, Thureau S, Petit T, Simon G, Frénel JS

Ther Adv Med Oncol. 2021 ;13:1758835920987657

Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients.

Carinato H, Burgy M, Ferry R, Fischbach C, Kalish M, Guihard S, Brahimi Y, Flesch H, Bronner G, Schultz P, Frasie V, Thiéry A, Demarchi M, Petit T, Jung AC, Wagner P, Coliat P, Borel C

Front Oncol. 2021 ;11:714551

Persistent taxane-induced neuropathy in elderly patients treated for localized breast cancer.

Pabst L, Velten M, Fischbach C, Kalish M, Pflumio C, Pivot X, Petit T

Breast J. 2020 Dec 11;:

Adjuvant Trastuzumab Is Required in Human Epidermal Growth Factor Receptor 2-Positive Node-Negative Breast Cancer Patients Regardless of Tumour Size.

Bender L, Kurtz JE, Petit T, Pivot X

J Breast Cancer. 2020 Dec;23(6):672-673

Impact of body mass index on overall survival in patients with metastatic breast cancer.

Saleh K, Carton M, Dieras V, Heudel PE, Brain E, D'Hondt V, Mailliez A, Patsouris A, Mouret-Reynier MA, Goncalves A, Ferrero JM, Petit T, Emile G, Uwer L, Debled M, Dalenc F, Jouannaud C, Ladoire S, Leheurteur M, Cottu P, Veron L, Savignoni A, Courtinard C, Robain M, Delaloge S, Deluche E

Breast. 2020 Dec 1;55:16-24

Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study.

Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Du FL, Dupré PF, Bachelot T, Gabelle P, Chauvet MP, Coeffic D, Barbe C, Prevost JB, Paintaud G, Thibault G, Ferhat A, Dupin J, Berriolo-Riedinger A, Arnould L

EClinicalMedicine. 2020 Nov;28:100566

Cognitive rehabilitation program to improve cognition of cancer patients treated with chemotherapy: A 3-arm randomized trial.

Dos Santos M, Hardy-Léger I, Rigal O, Licaj I, Dauchy S, Levy C, Noal S, Segura C, Delcambre C, Allouache D, Parzy A, Barriere J, Petit T, Lange M, Capel A, Clarisse B, Grellard JM, Lefel J, Joly F

Cancer. 2020 Sep 30;:

Palliative care delivery according to age in 12,000 women with metastatic breast cancer: Analysis in the multicentre ESME-MBC cohort 2008-2016.

Frasca M, Sabathe C, Delaloge S, Galvin A, Patsouris A, Levy C, Mouret-Reynier MA, Desmoulins I, Vanlemmens L, Bachelot T, Goncalves A, Perotin V, Uwer L, Frenel JS, Ferrero JM, Bouleuc C, Eymard JC, Dieras V, Leheurteur M, Petit T, Dalenc F, Jaffre A, Chevrot M, Courtinard C, Mathoulin-Pelissier S

Eur. J. Cancer. 2020 Aug 14;137:240-249

Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study.

Heudel P, Delaloge S, Parent D, Madranges N, Levy C, Dalenc F, Brain E, Uwer L, D'Hondt V, Augereau P, Mailliez A, Perrin C, Frenel JS, Sablin MP, Mouret-Reynier MA, Vermeulin T, Eymard JC, Petit T, Ferrero JM, Ilie S, Goncalves A, Chenuc G, Robain M, Simon G, Perol D

Anticancer Res.. 2020 Jul;40(7):3905-3913

Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort.

Frank S, Carton M, Dubot C, Campone M, Pistilli B, Dalenc F, Mailliez A, Levy C, D'Hondt V, Debled M, Vermeulin T, Coudert B, Perrin C, Gonçalves A, Uwer L, Ferrero JM, Eymard JC, Petit T, Mouret-Reynier MA, Patsouris A, Guesmia T, Bachelot T, Robain M, Cottu P

Breast. 2020 Apr 23;52:50-57

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.

Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, Mouret-Reynier MA, Costan C, Meier W, Reinthaller A, Goh JC, L'Haridon T, Baron Hay S, Kommoss S, du Bois A, Kurtz JE,

Lancet Oncol.. 2020 Apr 16;:

[COVID-19 and people followed for breast cancer: French guidelines for clinical practice of Nice-St Paul de Vence, in collaboration with the Collège Nationale des Gynécologues et Obstétriciens Français (CNGOF), the Société d'Imagerie de la FEMme (SIFEM),

Gligorov J, Bachelot T, Pierga JY, Antoine EC, Balleyguier C, Barranger E, Belkacemi Y, Bonnefoi H, Bidard FC, Ceugnart L, Classe JM, Cottu P, Coutant C, Cutuli B, Dalenc F, Darai E, Dieras V, Dohollou N, Giacchetti S, Goncalves A, Hardy-Bessard AC, Houvenaeghel G, Jacquin JP, Jacot W, Levy C, Mathelin C, Nisand I, Petit T, Petit T, Poncelet E, Rivera S, Rouzier R, Salmon R, Scotté F, Spano JP, Uzan C, Zelek L, Spielmann M, Penault-Llorca F, Namer M, Delaloge S

Bull Cancer. 2020 Apr 1;:

Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.

Deluche E, Antoine A, Bachelot T, Lardy-Cleaud A, Dieras V, Brain E, Debled M, Jacot W, Mouret-Reynier MA, Goncalves A, Dalenc F, Patsouris A, Ferrero JM, Levy C, Lorgis V, Vanlemmens L, Lefeuvre-Plesse C, Mathoulin-Pelissier S, Petit T, Uwer L, Jouannaud C, Leheurteur M, Lacroix-Triki M, Courtinard C, Perol D, Robain M, Delaloge S

Eur. J. Cancer. 2020 Mar 2;129:60-70

Agranulocytosis Induced by Tamoxifen in a Breast Cancer Patient.

Herrscher H, Leblanc J, Petit T

Breast Care (Basel). 2020 Feb;15(1):72-74

Radiation therapy to the primary tumor for de novo metastatic breast cancer and overall survival in a retrospective multicenter cohort analysis.

Pons-Tostivint E, Kirova Y, Lusque A, Campone M, Geffrelot J, Rivera S, Mailliez A, Pasquier D, Madranges N, Firmin N, Crouzet A, Gonçalves A, Jankowski C, De La Motte Rouge T, Pouget N, De La Lande B, Mouttet-Boizat D, Ferrero JM, Uwer L, Eymard JC, Mouret-Reynier MA, Petit T, Courtinard C, Filleron T, Robain M, Dalenc F

Radiother Oncol. 2020 Jan 10;145:109-116

Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol.

Mallard J, Hucteau E, Schott R, Petit T, Demarchi M, Belletier C, Ben Abdelghani M, Carinato H, Chiappa P, Fischbach C, Kalish-Weindling M, Bousinière A, Dufour S, Favret F, Pivot X, Hureau TJ, Pagano AF

Front Oncol. 2020 ;10:1304

Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME).

Sirieix J, Fraisse J, Mathoulin-Pelissier S, Leheurteur M, Vanlemmens L, Jouannaud C, Diéras V, Lévy C, Ung M, Mouret-Reynier MA, Petit T, Coudert B, Brain E, Pistilli B, Ferrero JM, Goncalves A, Uwer L, Patsouris A, Tredan O, Courtinard C, Gourgou S, Frénel JS

Ther Adv Med Oncol. 2020 ;12:1758835920980548

PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer.

Bertucci A, Bertucci F, Zemmour C, Lerebours F, Pierga JY, Levy C, Dalenc F, Grenier J, Petit T, Berline M, Gonçalves A

Front Oncol. 2020 ;10:575978

Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort.

Pasquier D, Darlix A, Louvel G, Fraisse J, Jacot W, Brain E, Petit A, Mouret-Reynier MA, Goncalves A, Dalenc F, Deluche E, Fresnel JS, Augereau P, Ferrero JM, Geffrelot J, Fumet JD, Lecouillard I, Cottu P, Petit T, Uwer L, Jouannaud C, Leheurteur M, Dieras V, Robain M, Mouttet-Audouard R, Bachelot T, Courtinard C

Eur. J. Cancer. 2020 Jan;125:22-30

Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study.

Kaboré EG, Guenancia C, Vaz-Luis I, Di Meglio A, Pistilli B, Coutant C, Cottu P, Lesur A, Petit T, Dalenc F, Rouanet P, Arnaud A, Arsene O, Ibrahim M, Wassermann J, Boileau-Jolimoy G, Martin AL, Lemonnier J, André F, Arveux P

PLoS Med.. 2019 Dec;16(12):e1002989

[Endocrine adjuvant treatment specific features for young breast cancer women].

Petit T

Bull Cancer. 2019 Dec;106(12S1):S24-S27

Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort.

Darlix A, Louvel G, Fraisse J, Jacot W, Brain E, Debled M, Mouret-Reynier MA, Goncalves A, Dalenc F, Delaloge S, Campone M, Augereau P, Ferrero JM, Levy C, Fumet JD, Lecouillard I, Cottu P, Petit T, Uwer L, Jouannaud C, Leheurteur M, Dieras V, Robain M, Chevrot M, Pasquier D, Bachelot T

Br. J. Cancer. 2019 Nov 13;:

Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis.

Ferreira AR, Di Meglio A, Pistilli B, Gbenou AS, El-Mouhebb M, Dauchy S, Charles C, Joly F, Everhard S, Lambertini M, Coutant C, Cottu P, Lerebours F, Petit T, Dalenc F, Rouanet P, Arnaud A, Martin A, Berille J, Ganz PA, Partridge AH, Delaloge S, Michiels S, Andre F, Vaz-Luis I

Ann. Oncol.. 2019 Nov;30(11):1784-1795

CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database.

Gougis P, Carton M, Tchokothe C, Campone M, Dalenc F, Mailliez A, Levy C, Jacot W, Debled M, Leheurteur M, Bachelot T, Hennequin A, Perrin C, Gonçalves A, Uwer L, Eymard JC, Petit T, Mouret-Reynier MA, Chamorey E, Simon G, Saghatchian M, Cailliot C, Le Tourneau C

Breast. 2019 Oct 19;49:17-24

Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients.

Herrscher H, Velten M, Leblanc J, Kalish-Weindling M, Fischbach C, Exinger D, Pivot X, Petit T

Breast Cancer Res. Treat.. 2019 Oct 14;:

Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis.

Ferreira AR, Di Meglio A, Pistilli B, Gbenou AS, El-Mouhebb M, Dauchy S, Charles C, Joly F, Everhard S, Lambertini M, Coutant C, Cottu P, Lerebours F, Petit T, Dalenc F, Rouanet P, Arnaud A, Martin A, Berille J, Ganz PA, Partridge AH, Delaloge S, Michiels S, Andre F, Vaz-Luis I

Ann. Oncol.. 2019 Oct 8;:

A new agent in the family of antibody-drug conjugates.

Pivot X, Petit T

Lancet Oncol.. 2019 Jun 27;:

Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program.

Jacot W, Heudel PE, Fraisse J, Gourgou S, Guiu S, Dalenc F, Pistilli B, Campone M, Levy C, Debled M, Leheurteur M, Chaix M, Lefeuvre C, Goncalves A, Uwer L, Ferrero JM, Eymard JC, Petit T, Mouret-Reynier MA, Courtinard C, Cottu P, Robain M, Mailliez A

Int. J. Cancer. 2019 May 14;:

Interest to consider re-challenging by cetuximab and platinum containing regimen in recurrent Head and Neck Cancer.

Borel C, Regnier-Gavier O, Carinato H, Guihard S, Antoni D, Demarchi M, Sirlin F, Exinger D, Petit-Jean E, Thiery A, Bronner G, Schultz P, Flesch H, Frasie V, Prébay D, Petit T, Jung AC, Burgy M, Coliat P

Oncotarget. 2018 Dec 25;9(101):37581-37588

Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched Analysis.

Pons-Tostivint E, Kirova Y, Lusque A, Campone M, Geffrelot J, Mazouni C, Mailliez A, Pasquier D, Madranges N, Firmin N, Crouzet A, Gonçalves A, Jankowski C, De La Motte Rouge T, Pouget N, de La Lande B, Mouttet-Boizat D, Ferrero JM, Uwer L, Eymard JC, Mouret-Reynier MA, Petit T, Robain M, Filleron T, Cailliot C, Dalenc F

Ann. Surg. Oncol.. 2018 Dec 11;:

Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.

Cabel L, Carton M, Cheaib B, Pierga JY, Dalenc F, Mailliez A, Levy C, Jacot W, Debled M, Leheurteur M, Desmoulins I, Lefeuvre C, Gonçalves A, Uwer L, Ferrero JM, Eymard JC, Petit T, Mouret-Reynier MA, Perrocheau G, Piot I, Pérol D, Simon G, Lerebours F

Breast Cancer Res. Treat.. 2018 Oct 24;:

Carboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) vs. carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: A prospective randomized phase III ENGOT/GCIG-Intergroup study (AGO study group, AGO-Austria, ANZG

Pfisterer J, Dean AP, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Shannon C, Hein A, Reimer DU, Hanker LC, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Kurtz JE

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii332-viii333

Can we establish a hierarchy among trastuzumab biosimilar candidates?

Pivot X, Petit T

Br. J. Cancer. 2018 Jul 13;:

Milestones over the development of SB3, a trastuzumab biosimilar.

Pivot X, Bondarenko I, Petit T, Curtit E

Future Oncol. 2018 Jun 21;:

Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.

Gobbini E, Ezzalfani M, Dieras V, Bachelot T, Brain E, Debled M, Jacot W, Mouret-Reynier MA, Goncalves A, Dalenc F, Patsouris A, Ferrero JM, Levy C, Lorgis V, Vanlemmens L, Lefeuvre-Plesse C, Mathoulin-Pelissier S, Petit T, Uwer L, Jouannaud C, Leheurteur M, Lacroix-Triki M, Cleaud AL, Robain M, Courtinard C, Cailliot C, Perol D, Delaloge S

Eur. J. Cancer. 2018 Apr 13;96:17-24

Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.

Bignon L, Fricker JP, Nogues C, Mouret-Fourme E, Stoppa-Lyonnet D, Caron O, Lortholary A, Faivre L, Lasset C, Mari V, Gesta P, Gladieff L, Hamimi A, Petit T, Velten M

Breast J. 2017 Sep;:

Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes.

Curtit E, Pivot X, Henriques J, Paget-Bailly S, Fumoleau P, Rios M, Bonnefoi H, Bachelot T, Soulié P, Jouannaud C, Bourgeois H, Petit T, Tennevet I, Assouline D, Mathieu MC, Jacquin JP, Lavau-Denes S, Darut-Jouve A, Ferrero JM, Tarpin C, Lévy C, Delecroix V, Trillet-Lenoir V, Cojocarasu O, Meunier J, Pierga JY, Kerbrat P, Faure-Mercier C, Blanché H, Sahbatou M, Boland A, Bacq D, Besse C, Thomas G, Deleuze JF, Pauporté I, Romieu G, Cox DG

Breast Cancer Res.. 2017 Aug;19(1):98

Efficacy and Safety of Pertuzumab and Trastuzumab Administered in a Single Infusion Bag, Followed by Vinorelbine: VELVET Cohort 2 Final Results.

Andersson M, López-Vega JM, Petit T, Zamagni C, Easton V, Kamber J, Restuccia E, Perez EA

Oncologist. 2017 Jun;:

Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.

Pierga JY, Bidard FC, Autret A, Petit T, Andre F, Dalenc F, Levy C, Ferrero JM, Romieu G, Bonneterre J, Lerebours F, Bachelot T, Kerbrat P, Campone M, Eymard JC, Mouret-Reynier MA, Gligorov J, Hardy-Bessard AC, Lortholary A, Soulie P, Boher JM, Proudhon C, Charafe-Jaufret E, Lemonnier J, Bertucci F, Viens P

Ann. Oncol.. 2017 Jan;28(1):103-109

Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort.

Pivot X, Romieu G, Fumoleau P, Rios M, Bonnefoi H, Bachelot T, Soulié P, Jouannaud C, Bourgeois H, Petit T, Tennevet I, Assouline D, Mathieu MC, Jacquin JP, Lavau-Denes S, Darut-Jouve A, Ferrero JM, Tarpin C, Lévy C, Delecroix V, Trillet-Lenoir V, Cojocarasu O, Meunier J, Pierga JY, Agostini C, Kerbrat P, Faure-Mercier C, Blanché H, Sahbatou M, Boland A, Bacq D, Besse C, Calvo F, Renaud A, Deleuze JF, Pauporté I, Thomas G, Cox DG

NPJ Breast Cancer. 2017 ;3:4

Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results.

Perez EA, López-Vega JM, Petit T, Zamagni C, Easton V, Kamber J, Restuccia E, Andersson M

Breast Cancer Res.. 2016 Dec;18(1):126

GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients.

Cox DG, Curtit E, Romieu G, Fumoleau P, Rios M, Bonnefoi H, Bachelot T, Soulié P, Jouannaud C, Bourgeois H, Petit T, Tennevet I, Assouline D, Mathieu MC, Jacquin JP, Lavau-Denes S, Darut-Jouve A, Ferrero JM, Tarpin C, Lévy C, Delecroix V, Trillet-Lenoir V, Cojocarasu O, Meunier J, Pierga JY, Faure-Mercier C, Blanché H, Sahbatou M, Boland A, Bacq D, Besse C, Deleuze JF, Pauporté I, Thomas G, Pivot X

Oncotarget. 2016 Nov;7(47):77358-77364

Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.

Delaloge S, Pérol D, Courtinard C, Brain E, Asselain B, Bachelot T, Debled M, Dieras V, Campone M, Levy C, Jacot W, Lorgis V, Veyret C, Dalenc F, Ferrero JM, Uwer L, Kerbrat P, Goncalves A, Mouret-Reynier MA, Petit T, Jouannaud C, Vanlemmens L, Chenuc G, Guesmia T, Robain M, Cailliot C

Ann. Oncol.. 2016 Sep;27(9):1725-32

[Breast cancer screening: On our way to the future].

Delaloge S, Bachelot T, Bidard FC, Espie M, Brain E, Bonnefoi H, Gligorov J, Dalenc F, Hardy-Bessard AC, Azria D, Jacquin JP, Lemonnier J, Jacot W, Goncalves A, Coutant C, Ganem G, Petit T, Penault-Lorca F, Debled M, Campone M, Levy C, Coudert B, Lortholary A, Venat-Bouvet L, Grenier J, Bourgeois H, Asselain B, Arvis J, Castro M, Tardivon A, Cox DG, Arveux P, Balleyguier C, André F, Rouzier R,

Bull Cancer. 2016 Sep;103(9):753-63

A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study.

Trédan O, Follana P, Moullet I, Cropet C, Trager-Maury S, Dauba J, Lavau-Denes S, Diéras V, Béal-Ardisson D, Gouttebel M, Orfeuvre H, Stefani L, Jouannaud C, Bürki F, Petit T, Guardiola E, Becuwe C, Blot E, Pujade-Lauraine E, Bachelot T

Ann. Oncol.. 2016 Jun;27(6):1020-9

Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.

Bertucci F, Fekih M, Autret A, Petit T, Dalenc F, Levy C, Romieu G, Bonneterre J, Ferrero JM, Kerbrat P, Soulie P, Mouret-Reynier MA, Bachelot T, Lerebours F, Eymard JC, Deblock M, Lortholary A, Hardy-Bessard AC, Barthelemy P, Bonnefoi H, Charafe-Jauffret E, Bidard FC, Viens P, Lemonnier J, Pierga JY

Lancet Oncol.. 2016 May;17(5):600-11

MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.

Tabouret E, Bertucci F, Pierga JY, Petit T, Levy C, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, van Laere S, Ueno NT, Toiron Y, Finetti P, Birnbaum D, Borg JP, Viens P, Chinot O, Gonçalves A

Oncotarget. 2016 Apr;7(14):18531-40

Does the Number of Neoadjuvant Chemotherapy Cycles before Interval Debulking Surgery Influence Survival in Advanced Ovarian Cancer?

Akladios C, Baldauf JJ, Marchal F, Hummel M, Rebstock LE, Kurtz JE, Petit T, Afors K, Mathelin C, Lecointre L, Schrot-Sanyan S

Oncology. 2016 ;91(6):331-340

Impact of screening on clinicopathological features and treatment for invasive breast cancer: results of two national surveys.

Cutuli B, Dalenc F, Cottu PH, Gligorov J, Guastalla JP, Petit T, Amrate A

Cancer Radiother. 2015 Aug;19(5):295-302

PIK3CA pathway mutations predictive of poor response following Standard radio chemotherapy +/- Cetuximab in cervical cancer patients.

de la Rochefordiere A, Kamal M, Floquet A, Thomas L, Petrow P, Petit T, Pop M, Fabbro M, Kerr C, Joly F, Sevin E, Maillard S, Cure H, Weber B, Brunaud C, Minsat M, Gonzague L, Berton-Rigaud D, Aumont M, Gladieff L, Peigneux K, Bernard V, Leroy Q, Bieche I, Margogne A, Nadan AT, Fourchotte V, Diallo A, Asselain B, Plancher C, Armanet S, Beuzeboc P, Scholl S

Clin Cancer Res. 2015 Feb 27. pii: clincanres.2368.2014.

Folliculotropic T-cell infiltrates associated with B-cell chronic lymphocytic leukaemia or MALT lymphoma may reveal either true mycosis fungoides or pseudolymphomatous reaction: seven cases and review of the literature.

Ingen-Housz-Oro S, Franck N, Beneton N, Fauconneau A, Do-Pham G, Carlotti A, Petit T, Liolios I, Bara C, Carpentier H, Storelli D, Prophette B, Garderet L, Haioun C, Petit E, Delfau-Larue MH, Vergier B, Chosidow O, Beylot-Barry M, Ortonne N

J Eur Acad Dermatol Venereol. 2015 Jan;29(1):77-85

Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study.

Bonnefoi H, Jacot W, Saghatchian M, Moldovan C, Venat-Bouvet L, Zaman K, Matos E, Petit T, Bodmer A, Quenel-Tueux N, Chakiba C, Vuylsteke P, Jerusalem G, Brain E, Tredan O, Messina CG, Slaets L, Cameron D

Ann Oncol. 2014 Dec 1. pii: mdu551.

Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data.

Pierga J, Petit T, Levy C, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roche H, Bachelot T, Charafe-Jauffret EA, Bonneterre J, Hernandez J, Bidard F, Viens P

Clin Cancer Res. 2014 Dec 23. pii: clincanres.1705.2014.

Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER):

Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Kerbrat P, Dupre PF, Bachelot T, Gabelle P, Giard S, Coeffic D, Bougnoux P, Prevost JB, Paintaud G, Thibault G, Hernandez J, Coudert M, Arnould L, Berriolo-Riedinger A

Lancet Oncol. 2014 Dec;15(13):1493-502

[Use of guidelines and heterogeneity of decision making for adjuvant chemotherapy in hormone-receptor positive, HER2-negative, early breast cancer: results of a French national survey].

Fekih M, Petit T, Zarca D, Guinebretiere JM, Andre F, Pierga JY, Namer M, Gligorov J, Delaloge S

Bull Cancer. 2014 Oct;101(10):918-24

Morphologic and molecular study of hemoparasites in wild corvids and evidence of sequence identity with Plasmodium DNA detected in captive black-footed penguins (Spheniscus demersus).

Leclerc A, Chavatte JM, Landau I, Snounou G, Petit T

J. Zoo Wildl. Med.. 2014 Sep;45(3):577-88

Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.

Nabholtz JM, Abrial C, Mouret-Reynier MA, Dauplat MM, Weber B, Gligorov J, Forest AM, Tredan O, Vanlemmens L, Petit T, Guiu S, Van Praagh I, Jouannaud C, Dubray-Longeras P, Tubiana-Mathieu N, Benmammar KE, Kullab S, Bahadoor MR, Radosevic-Robin N, Kwiatkowski F, Desrichard A, Cayre A, Uhrhammer N, Chalabi N, Chollet P, Penault-Llorca F

Ann Oncol. 2014 Aug;25(8):1570-7

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.

Bonnefoi H, Litiere S, Piccart M, MacGrogan G, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Moldovan C, Bodmer A, Zaman K, Cufer T, Campone M, Luporsi E, Malmstrom P, Werutsky G, Bogaerts J, Bergh J, Cameron DA

Ann Oncol. 2014 Jun;25(6):1128-36

Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study.

Tredan O, Treilleux I, Wang Q, Gane N, Pissaloux D, Bonnin N, Petit T, Cretin J, Bonichon-Lamichhane N, Priou F, Lavau-Denes S, Mari V, Freyer G, Lebrun D, Alexandre J, Ray-Coquard I

Target Oncol. 2013 Dec;8(4):243-51

[Breast cancer: a multidisciplinary management].

Petit T

Rev Prat. 2013 Dec;63(10):1393-4.

Esophageal atresia: data from a national cohort.

Sfeir R, Bonnard A, Khen-Dunlop N, Auber F, Gelas T, Michaud L, Podevin G, Breton A, Fouquet V, Piolat C, Lemelle JL, Petit T, Lavrand F, Becmeur F, Polimerol ML, Michel JL, Elbaz F, Habonimana E, Allal H, Lopez E, Lardy H, Morineau M, Pelatan C, Merrot T, Delagausie P, de Vries P, Levard G, Buisson P, Sapin E, Jaby O, Borderon C, Weil D, Gueiss S, Aubert D, Echaieb A, Fourcade L, Breaud J, Laplace C, Pouzac M, Duhamel A, Gottrand F

J Pediatr Surg. 2013 Aug;48(8):1664-9

Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial.

Lheureux S, Krieger S, Weber B, Pautier P, Fabbro M, Selle F, Bourgeois H, Petit T, Lortholary A, Plantade A, Briand M, Leconte A, Richard N, Vilquin P, Clarisse B, Blanc-Fournier C, Joly F

Int J Gynecol Cancer. 2012 Nov;22(9):1483-8

Neoadjuvant chemoradiotherapy followed by surgery in locally advanced squamous cell carcinoma of the vulva.

Gaudineau A, Weitbruch D, Quetin P, Heymann S, Petit T, Volkmar P, Bodin F, Velten M, Rodier JF

Oncol Lett. 2012 Oct;4(4):719-722

Outcome of alimentary tract duplications operated on by minimally invasive surgery: a retrospective multicenter study by the GECI (Groupe d'Etude en Coeliochirurgie Infantile).

Guerin F, Podevin G, Petit T, Lopez M, de Lagausie P, Lardy H, Bonnard A, Becmeur F, Philippe P, Larroquet M, Sapin E, Kurzenne JY, le Mandat A, Francois-Fiquet C, Gaudin J, Valioulis I, Morisson-Lacombe G, Montupet P, Demarche M

Surg Endosc. 2012 Oct;26(10):2848-55

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.

Pierga JY, Petit T, Delozier T, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roche H, Bachelot T, Charafe-Jauffret E, Pavlyuk M, Kraemer S, Bidard FC, Viens P

Lancet Oncol. 2012 Apr;13(4):375-84

Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.

Coudert B, Asselain B, Campone M, Spielmann M, Machiels JP, Penault-Llorca F, Serin D, Levy C, Romieu G, Canon JL, Orfeuvre H, Piot G, Petit T, Jerusalem G, Audhuy B, Veyret C, Beauduin M, Eymard JC, Martin AL, Roche H

Oncologist. 2012;17(7):900-9

[Node negative breast cancer. Beyond international consensus: a pragmatic approach].

Penault-Llorca F, Coeffic D, Delozier T, Dohollou N, Freyer G, Gligorov J, Hardy-Bessard AC, Jacot W, Misset JL, Nabholtz JM, Petit T, Spielmann M, Namer M

Bull Cancer. 2011 Jul;98(7):807-25.

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.

Bonnefoi H, Piccart M, Bogaerts J, Mauriac L, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Blot E, Zaman K, Cufer T, Lortholary A, Lidbrink E, Andre S, Litiere S, Lago LD, Becette V, Cameron DA, Bergh J, Iggo R

Lancet Oncol. 2011 Jun;12(6):527-39

Retraction--Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.

Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot E, Becette V, Farmer P, Andre S, Acharya CR, Mukherjee S, Cameron D, Bergh J, Nevins JR, Iggo RD

Lancet Oncol. 2011 Feb;12(2):116.

A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer.

Petit T, Dufour P, Tannock I

Endocr Relat Cancer. 2011 Jun 8;18(3):R79-89. Print 2011.

Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.

Petit T, Wilt M, Velten M, Rodier JF, Fricker JP, Dufour P, Ghnassia JP

Breast Cancer Res Treat. 2010 Nov;124(2):387-91

Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).

Pautier P, Joly F, Kerbrat P, Bougnoux P, Fumoleau P, Petit T, Rixe O, Ringeisen F, Carrasco AT, Lhomme C

Gynecol Oncol. 2010 Feb;116(2):157-62.

Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study.

Joly F, Petit T, Pautier P, Guardiola E, Mayer F, Chevalier-Place A, Delva R, Sevin E, Henry-Amar M, Bourgeois H

Gynecol Oncol. 2009 Dec;115(3):382-8

Third consensus on medical treatment of metastatic breast cancer.

Beslija S, Bonneterre J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V, Jassem J, Kostler WJ, Krainer M, Menard S, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, Wilcken N, Wiltschke C, Zielinski CC, Zwierzina H

Ann Oncol. 2009 Nov;20(11):1771-85

[Prevalent metastatic axillary lymphadenopathy from ovarian cancer: a diagnostic pitfall]

Rodier JF, Dupret A, Weitbruch D, Volkmar PP, Wilt M, Petit T

J Chir (Paris). 2009 Apr;146(2):226-7

A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer.

Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, Andre S, Piccart M, Campone M, Brain E, Macgrogan G, Petit T, Jassem J, Bibeau F, Blot E, Bogaerts J, Aguet M, Bergh J, Iggo R, Delorenzi M

Nat Med. 2009 Jan;15(1):68-74

Adjuvant chemotherapy of breast cancers with overexpression or HER2 amplification.

Petit T

Oncologie. 2008 Apr;10 4:S64-7.

Metastatic breast cancers

Campone M, Deplanque G, Dohollou N, Gligorov J, Largillier R, Namer M, Penault-Llorca E, Petit T, Spielmann M, Zelek L

Oncologie. 2008 Feb;10(2):136-48

Laparoscopic resection of abdominal neuroblastoma.

Leclair MD, de Lagausie P, Becmeur F, Varlet F, Thomas C, Valla JS, Petit T, Philippe-Chomette P, Mure PY, Sarnacki S, Michon J, Heloury Y

Ann Surg Oncol. 2008 Jan;15(1):117-24

Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.

Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot E, Becette V, Farmer P, Andre S, Acharya CR, Mukherjee S, Cameron D, Bergh J, Nevins JR, Iggo RD

Lancet Oncol. 2007 Dec;8(12):1071-8

Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy.

Petit T, Velten M, d'Hombres A, Marchal C, Montbarbon X, Mornex F, Quetin P, Gerard JP, Romestaing P, Carrie C

Gynecol Oncol. 2007 Jan;104(1):104-8

Gemcitabine and epirubicin in patients with metastatic breast cancer: a phase I/II study.

Campone M, Fumoleau P, Viens P, Dieras V, Pujade-Lauraine E, Serin D, Petit T, Espie M, Kayitalire L, Bozec L, Pouillart P

Breast. 2006 Oct;15(5):601-9.

A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients.

Viens P, Petit T, Yovine A, Bougnoux P, Deplanque G, Cottu PH, Delva R, Lotz JP, Belle SV, Extra JM, Cvitkovic E

Ann Oncol. 2006 Mar;17(3):429-36.

Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline- and taxane-pre-treated metastatic breast cancer.

Petit T, Benider A, Yovine A, Bougnoux P, Spaeth D, Maindrault-Goebel F, Serin D, Tigaud JD, Eymard JC, Simon H, Bertaux B, Brienza S, Cvitkovic E

Anticancer Drugs. 2006 Mar;17(3):337-43.

Lymphopenia: a new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma.

Claude L, Perol D, Ray-Coquard I, Petit T, Blay JY, Carrie C, Bachelot T

Radiother Oncol. 2005 Sep;76(3):334-9

Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy.

Petit T, Wilt M, Velten M, Millon R, Rodier JF, Borel C, Mors R, Haegele P, Eber M, Ghnassia JP

Eur J Cancer. 2004 Jan;40(2):205-11.

Fiche personne

Coordonnées

Territoire

Statut

Affiliation

Équipes/plateformes

Publications